Evidence map›Paper›PMID 40878817›Full record

ArticleAnnals of clinical and translational neurology2025

A Validated Model to Predict Severe Weight Loss in Amyotrophic Lateral Sclerosis.

David G Lester, Kevin Talbot, Martin R Turner, Alexander G Thompson, Pooled Resource Open‐Access ALS Clinical Trials Consortium

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

David G LesterNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0002-5507-0781
Kevin TalbotNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Martin R TurnerNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0003-0267-3180
Alexander G ThompsonNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0003-1063-3277
Pooled Resource Open‐Access ALS Clinical Trials Consortium

Funding

Medical Research Council MR/T006927/1Medical Research Council MR/Y001095/1Motor Neurone Disease Association Lester/2450/795Motor Neurone Disease Association Thompson/Jan20/952-795
6 · The paper itself

Abstract

Severe weight loss in amyotrophic lateral sclerosis (ALS) is common, multifactorial, and associated with shortened survival. Using longitudinal weight data from over 6000 patients with ALS across three cohorts, we built an accelerated failure time model to predict the risk of future severe (≥ 10%) weight loss using five single-timepoint clinical predictors: symptom duration, revised ALS Functional Rating Scale, site of onset, forced vital capacity, and age. Model performance and generalisability were evaluated using internal-external cross-validation and random-effects meta-analysis. The overall concordance statistic was 0.71 (95% CI 0.63-0.79), and the calibration slope and intercept were 0.91 (0.69-1.13) and 0.05 (-0.11-0.21). This study highlights clinical factors most associated with severe weight loss in ALS and provides the basis for a stratification tool.

Indexed as

Amyotrophic Lateral SclerosisWeight LossAdultAgedFemaleHumansMaleMiddle AgedSeverity of Illness Indexamyotrophic lateral sclerosisclinical prediction modelmotor neuron diseasenutritionweight loss

Identifiers

PMID40878817
PMCPMC12455886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.